Cargando…
A Panorama of Immune Fighters Armored with CARs in Acute Myeloid Leukemia
SIMPLE SUMMARY: Acute myeloid leukemia (AML) is a difficult-to-treat cancer, and chemotherapy can cause severe side effects. Patients may need stem cell transplantation, but this is challenging and not always successful. Even with intensive treatment, some patients may relapse or develop a refractor...
Autores principales: | Christodoulou, Ilias, Solomou, Elena E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252303/ https://www.ncbi.nlm.nih.gov/pubmed/37297016 http://dx.doi.org/10.3390/cancers15113054 |
Ejemplares similares
-
Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy
por: Hawkins, Elizabeth R, et al.
Publicado: (2021) -
Fighters of Fate
Publicado: (1928) -
Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy
por: Marofi, Faroogh, et al.
Publicado: (2021) -
CAR-T Cells Immunotherapies for the Treatment of Acute Myeloid Leukemia—Recent Advances
por: Zarychta, Julia, et al.
Publicado: (2023) -
Acute myeloid leukemia therapeutics: CARs in the driver’s seat
por: Mardiros, Armen, et al.
Publicado: (2013)